Palliative Care

Clinical Practice Guidelines in Oncology

Michael Levy, MD, PhD; Thomas Smith, MD; Amy Alvarez-Perez, MD; Anthony Back, MD; Justin N. Baker, MD; Anna C. Beck, MD; Susan Block, MD; Shalini Dalal, MD; Maria Dans, MD; Thomas R. Fitch, MD; Jennifer Kapo, MD; Jean S. Kutner, MD; Elizabeth Kvale, MD; Sumathi Misra, MD; William Mitchell, MD; Diane G. Portman, MD; Todd M. Sauer, MD; David Spiegel, MD; Linda Sutton, MD; Eytan Szmuilowicz, MD; Robert M. Taylor, MD; Jennifer Temel, MD; Roma Tickoo, MD, MPH; Susan G. Urba, MD; Elizabeth Weinstein, MD; Finly Zachariah, MD; Mary Anne Bergman; and Jillian L. Scavone, PhD

Abstract

The NCCN Guidelines for Palliative Care provide interdisciplinary recommendations on palliative care for patients with cancer. The NCCN Guidelines are intended to provide guidance to the primary oncology team on the integration of palliative care into oncology. The NCCN Palliative Care Panel's recommendations seek to ensure that each patient experiences the best quality of life possible throughout the illness trajectory. Accordingly, the NCCN Guidelines outline best practices for screening, assessment, palliative care interventions, reassessment, and after-death care.

J Natl Compr Canc Netw 2016;14(1):82–113

NCCN Categories of Evidence and Consensus

Category 1: Based upon high-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2A: Based upon lower-level evidence, there is uniform NCCN consensus that the intervention is appropriate.

Category 2B: Based upon lower-level evidence, there is NCCN consensus that the intervention is appropriate.

Category 3: Based upon any level of evidence, there is major NCCN disagreement that the intervention is appropriate.

All recommendations are category 2A unless otherwise noted.

Clinical trials: NCCN believes that the best management for any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged.

Please Note

The NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines®) are a statement of consensus of the authors regarding their views of currently accepted approaches to treatment. Any clinician seeking to apply or consult the NCCN Guidelines® is expected to use independent medical judgment in the context of individual clinical circumstances to determine any patient's care or treatment. The National Comprehensive Cancer Network® (NCCN®) makes no representation or warranties of any kind regarding their content, use, or application and disclaims any responsibility for their applications or use in any way. The full NCCN Guidelines for Palliative Care are not printed in this issue of JNCCN but can be accessed online at NCCN.org.

© National Comprehensive Cancer Network, Inc. 2016. All rights reserved. The NCCN Guidelines and the illustrations herein may not be reproduced in any form without the express written permission of NCCN.

Disclosures for the NCCN Palliative Care Panel

At the beginning of each NCCN Guidelines panel meeting, panel members review all potential conflicts of interest. NCCN, in keeping with its commitment to public transparency, publishes these disclosures for panel members, staff, and NCCN itself.

Individual disclosures for the NCCN Palliative Care Panel members can be found on page 113. (The most recent version of these guidelines and accompanying disclosures are available on the NCCN Web site at NCCN.org.)

These guidelines are also available on the Internet. For the latest update, visit NCCN.org.
The NCCN Guidelines for Palliative Care were developed to facilitate the appropriate integration of palliative care into oncology practice. The guidelines outline procedures for screening, assessment, palliative care interventions, reassessment, and after-death care.

**Palliative Care Screening**

The primary oncology team should screen all patients at every visit for one or more of the following: 1) unmanaged symptoms; 2) moderate to severe distress related to cancer diagnosis and therapy; 3) serious comorbid physical, psychiatric, and psychosocial conditions; 4) life expectancy of 6 months or less; 5) metastatic solid tumors; 6) patient or family concerns about the course of disease and decision-making; and/or 7) patient or family requests for palliative care. Patients who meet these screening criteria and those who make a specific request for palliative care should undergo a full palliative care assessment.

Patients who do not meet these screening criteria should undergo re-screening at the next visit. In addition, the oncology team should inform patients and family members about palliative care services. Anticipation of palliative care needs and prevention of symptoms should also be discussed, and conversations regarding advance care planning should be initiated.

**Palliative Care Assessment**

Patients who meet screening criteria (see previous section) should undergo a comprehensive palliative care

---

*Michael Levy, MD, PhD/Chair†£
Fox Chase Cancer Center

*Thomas Smith, MD/Vice-Chair†£
The Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins

Amy Alvarez-Perez, MD†£
Roswell Park Cancer Institute

Anthony Back, MD†£
Fred Hutchinson Cancer Research Center/
Seattle Cancer Care Alliance

Justin N. Baker, MD†
St. Jude Children’s Research Hospital/
The University of Tennessee Health Science Center

Anna C. Beck, MD†
Huntsman Cancer Institute at the University of Utah

Susan Block, MD†
Dana-Farber/Brigham and Women’s Cancer Center

Shalini Dalal, MD†
The University of Texas MD Anderson Cancer Center

Maria Dans, MD†
Siteman Cancer Center at Barnes-Jewish Hospital and Washington University School of Medicine

Thomas R. Fitch, MD†
Mayo Clinic Cancer Center

Jennifer Kapo, MD†£
Yale Cancer Center/Smilow Cancer Hospital

Jean S. Kutner, MD†£
University of Colorado Cancer Center

Elizabeth Kvale, MD†
University of Alabama at Birmingham Comprehensive Cancer Center

Sumathi Misra, MD†£
Vanderbilt-Ingram Cancer Center

William Mitchell, MD†
UC San Diego Moores Cancer Center

Diane G. Portman, MD†
Moffitt Cancer Center

Todd M. Sauer, MD†
Fred & Pamela Buffett Cancer Center

David Spiegel, MD†
Stanford Cancer Institute

Linda Sutton, MD†£
Duke Cancer Institute

Eytan Szmuilowicz, MD†
Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Robert M. Taylor, MD†£
The Ohio State University Comprehensive Cancer Center - James Cancer Hospital and Solove Research Institute

Jennifer Temel, MD†£
Massachusetts General Hospital Cancer Center

Roma Tickoo, MD, MPH†£
Memorial Sloan Kettering Cancer Center

Susan G. Urba, MD†£
University of Michigan Comprehensive Cancer Center

Elizabeth Weinstein, MD†£
Case Comprehensive Cancer Center/
University Hospitals Seidman Cancer Center and Cleveland Clinic Taussig Cancer Institute

Finly Zachariah, MD†
City of Hope Comprehensive Cancer Center

NCCN Staff: Mary Anne Bergman and Jillian L. Scavone, PhD

KEY:

*Writing Committee Member

Specialties: †Medical Oncology; ‡Hematology/Hematology-Oncology; §Supportive Care, Including Palliative and Pain Management; ¶Anesthesiology; ©Pediatric Oncology; ©Geriatric Medicine; ©Internal Medicine; ©Psychiatry and Psychology, Including Health Behavior; ¥Neurology/Neuro-Oncology
Clinical trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 14 Number 1 | January 2016

**SCREENING**

One or more of the following:
- Uncontrolled symptoms
- Moderate-to-severe distress related to cancer diagnosis and cancer therapy
- Serious comorbid physical and psychosocial conditions
- Life expectancy ≤6 mo
- Metastatic solid tumors
- Patient/family concerns about course of disease and decision-making
- Patient/family requests for palliative care

**ASSESSMENT**

Ongoing reassessment

- Benefits/burdens of anticancer therapy
- Personal goals/values/expectations
- Symptoms
- Psychosocial or spiritual distress
- Educational and informational needs
- Cultural factors affecting care
- Criteria for consultation with palliative care specialist

**ESTIMATED LIFE EXPECTANCY**

- Years
- Years to months
- Months to weeks
- Weeks to days (Dying patient)

**PALLIATIVE CARE INTERVENTIONS**

- Anticancer therapy
- Appropriate treatment of comorbid physical and psychosocial conditions
- Coordination of care with other health care providers
- Symptom management
- Advance care planning
- Psychosocial and spiritual support
- Culturally appropriate care
- Resource management/social support
- Consultation with palliative care specialist
- Hospice referral
- Response to request to withdraw or withhold life-sustaining treatment
- Response to requests for hastened death (physician-assisted suicide and euthanasia)
- Care of imminently dying patient
- Palliative sedation

**REASSESSMENT**

Acceptable:
- Patient satisfied with response to anticancer therapy
- Adequate pain and symptom management
- Reduction of patient/family distress
- Acceptable sense of control
- Relief of caregiver burden
- Strengthened relationships
- Optimized quality of life
- Personal growth and enhanced meaning

Unacceptable

- Intensify palliative care interventions
- Consult or refer to specialized palliative care services or hospice

**AFTER-DEATH INTERVENTIONS**

- For family and caregiver(s):
  - Immediate after-death care
  - Bereavement support
  - Cancer risk assessment and modification
- For health care team:
  - General support
  - After-death support

**Assessment by Oncology Team (PAL-3)**

**Notes**

- Patients who screen positive require a care plan developed by an interdisciplinary team of physicians, nurses, social workers, and other mental health professionals, chaplains, nurse practitioners, physician assistants, and dietitians.
- Oncologists should integrate palliative care into general oncology care. Early consultation/collaboration with a palliative care specialist/hospice team should be considered to improve quality of life and survival.
Oncologists should integrate palliative care into general oncology care. Early consultation/collaboration with a palliative care specialist/hospice team should be considered to improve quality of life and survival.

Patients who screen positive require a care plan developed by an interdisciplinary team of physicians, nurses, social workers, and other mental health professionals, chaplains, nurse practitioners, physician assistants, and dietitians.

Oncologists should integrate palliative care into general oncology care. Early consultation/collaboration with a palliative care specialist/hospice team should be considered to improve quality of life and survival.

---

**SCREENING**

- Uncontrolled symptoms
- Moderate-to-severe distress related to cancer diagnosis and/or cancer therapy
- Serious comorbid physical, psychiatric, and psychosocial conditions
- Metastatic solid tumors
- Life expectancy ≤6 mo

**ASSESSMENT BY ONCOLOGY TEAM**

- Benefits/burdens of anticancer therapy
- Symptoms
- Psychosocial distress
- Personal goals/values/expectations
- Educational and informational needs
- Cultural factors affecting care

Not present

- Inform the patient and family about palliative care services
  - Anticipate symptoms and discuss preventative measures
  - Discuss advance care planning
  - Rescreen at next visit

Present

See PAL-4

See PAL-6

See PAL-6 and PAL-7

---

Available online, in these guidelines, at NCCN.org.

**Notes:**

1. Patients who screen positive require a care plan developed by an interdisciplinary team of physicians, nurses, social workers, and other mental health professionals, chaplains, nurse practitioners, physician assistants, and dietitians.

2. Oncologists should integrate palliative care into general oncology care. Early consultation/collaboration with a palliative care specialist/hospice team should be considered to improve quality of life and survival.
### Palliative Care, Version 1.2016

#### BENEFITS/BURDENS OF ANTICANCER THERAPY

<table>
<thead>
<tr>
<th>ESTIMATED LIFE EXPECTANCY</th>
<th>INTERVENTIONS</th>
<th>REASSESSMENT</th>
</tr>
</thead>
</table>
| **Years**                 | • Discuss whether anticancer therapy is palliative or curative  
• Review the burdens of anticancer therapy, including possible effects on quality of life  
• Assess understanding of prognosis and goals of therapy  
• Provide appropriate anticancer therapy as outlined in NCCN disease-specific guidelines*  
• Provide appropriate prevention and management of symptoms caused by anticancer therapy  
• Provide appropriate palliative care  
• Prepare patient psychologically for possible disease progression  
| Acceptable:  
• Adequate pain and symptom management  
• Reduction of patient/family distress  
• Acceptable sense of control  
• Relief of caregiver burden  
• Strengthened relationships  
• Optimized quality of life  
• Personal growth and enhanced meaning  
| Continue anticancer therapy and palliative care  
| Ongoing reassessment |
| **Year to months**        | • Confirm the patient's understanding of incurability of disease  
Offer best supportive care, including referral to palliative care or hospice  
• Redirect goals and hopes to those that are achievable based on likely prognosis and life expectancy  
• Provide guidance regarding anticipated course of disease  
• Consider discontinuation of anticancer treatment  
| Unacceptable  
| • Change or discontinue anticancer therapy  
• Review patient hopes about and meaning of anticancer therapy  
• Intensify palliative care interventions  
• Review advance care planning  
• Consult or refer to specialized palliative care services or hospice  
|  
| **Months to weeks**       | • Discontinue anticancer therapy  
• Intensify palliative care in preparation for death  
• Provide guidance regarding anticipated dying process  
• Focus on symptom management and comfort  
• Foster patient participation in preparing loved ones  
• Refer to palliative care/hospice team  
|  
| **Weeks to days**         |  
(Next to weeks)  
(Dying patient)  

*To view the most recent version of these guidelines, visit NCCN.org.

---

**Clinical trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 14 Number 1 | January 2016
Palliative Care, Version 1.2016

**PAIN**

**ESTIMATED LIFE EXPECTANCY**

- **Years**
- **Year to months**
- **Months to weeks**
- **Weeks to days** (Dying patient)

**INTERVENTIONS**

- Treat according to NCCN Guidelines for Adult Cancer Pain*
  - In addition:
    - Do not reduce dose of opioid solely for decreased blood pressure, respiration rate, or level of consciousness when opioid is necessary for adequate management of pain or dyspnea
    - Maintain analgesic therapy; titrate to optimal comfort
    - Recognize and treat opioid-induced neurotoxicity, including myoclonus and hyperalgesia
    - If opioid reduction is indicated, reduce by 25%-50% per 24 h to avoid acute opioid withdrawal or pain crisis. Avoid opioid antagonists
    - Balance analgesia against reduced level of consciousness based on patient preference
    - Modify routes of administration as needed (PO, IV, PR, subcutaneous, sublingual, transmucosal, and transdermal), applying equianalgesic dose conversions

**REASSESSMENT**

- Acceptable:
  - Adequate pain and symptom management
  - Reduction of patient/family distress
  - Acceptable sense of control
  - Relief of caregiver burden
  - Strengthened relationships
  - Optimized quality of life
  - Personal growth and enhanced meaning

- Unacceptable

*Continued to treat and Monitor symptoms and quality of life

- Ongoing reassessment

*To view the most recent version of these guidelines, visit NCCN.org.

**BENEFITS/BURDENS OF ANTICANCER THERAPY**

**ESTIMATED LIFE EXPECTANCY**

- **Years**
- **Year to months**
- **Months to weeks**
- **Weeks to days** (Dying patient)

**INTERVENTIONS**

- Discuss whether anticancer therapy is palliative or curative
- Review the burdens of anticancer therapy, including possible effects on quality of life
- Assess understanding of prognosis and goals of therapy
- Provide appropriate anticancer therapy as outlined in NCCN disease-specific guidelines*
- Provide appropriate prevention and management of symptoms caused by anticancer therapy
- Provide appropriate palliative care
- Prepare patient psychologically for possible disease progression

*Ongoing reassessment

- Confirm the patient's understanding of incurability of disease. Offer best supportive care, including referral to palliative care or hospice
- Redirect goals and hopes to those that are achievable based on likely prognosis and life expectancy
- Provide guidance regarding anticipated course of disease
- Consider discontinuation of anticancer treatment

- Acceptable:
  - Adequate pain and symptom management
  - Reduction of patient/family distress
  - Acceptable sense of control
  - Relief of caregiver burden
  - Strengthened relationships
  - Optimized quality of life
  - Personal growth and enhanced meaning

- Unacceptable

*Continued to treat and Monitor symptoms and quality of life

- Ongoing reassessment

*To view the most recent version of these guidelines, visit NCCN.org.
### Palliative Care, Version 1.2016

#### Clinical trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

**ESTIMATED LIFE EXPECTANCY**

- **Years**
  - Assess symptom intensity
  - Treat underlying causes/comorbid conditions:
    - Radiation/chemotherapy
    - Therapeutic procedure for cardiac, pleural, or abdominal fluid
    - Bronchoscopic therapy
    - Bronchodilators, diuretics, steroids, antibiotics, or transfusions
    - Anticoagulants for pulmonary emboli
  - Relieve symptoms
  - Oxygen therapy for symptomatic hypoxia
  - Educational, psychosocial, and emotional support for the patient and family
  - Nonpharmacologic therapies, including fans, cooler temperatures, stress management, relaxation therapy, and physical comfort measures
  - If opioid naive, morphine, 2.5–10 mg PO q 2 hr prn or 1–3 mg IV q 2 hr prn
  - If dyspnea is not relieved by opioids and is associated with anxiety, add benzodiazepines (if benzodiazepine naive, lorazepam, 0.5–1 mg PO q 4 hr pm)
  - Noninvasive positive-pressure ventilation (eg, CPAP, BiPAP) support if clinically indicated for severe reversible condition

- **Year to months**
  - See Interventions (PAL-12)

- **Months to weeks**
  - Assess symptom intensity
  - Treat underlying causes/comorbid conditions:
    - Radiation/chemotherapy
    - Therapeutic procedure for cardiac, pleural, or abdominal fluid
    - Bronchoscopic therapy
    - Bronchodilators, diuretics, steroids, antibiotics, or transfusions
    - Anticoagulants for pulmonary emboli
  - Relieve symptoms
  - Oxygen therapy for symptomatic hypoxia
  - Educational, psychosocial, and emotional support for the patient and family
  - Nonpharmacologic therapies, including fans, cooler temperatures, stress management, relaxation therapy, and physical comfort measures
  - If opioid naive, morphine, 2.5–10 mg PO q 2 hr prn or 1–3 mg IV q 2 hr prn
  - If dyspnea is not relieved by opioids and is associated with anxiety, add benzodiazepines (if benzodiazepine naive, lorazepam, 0.5–1 mg PO q 4 hr pm)
  - Noninvasive positive-pressure ventilation (eg, CPAP, BiPAP) support if clinically indicated for severe reversible condition

- **Weeks to days (Dying patient)**
  - See Interventions (PAL-12)

**INTERVENTIONS**

**REASSESSMENT**

- **Acceptable:**
  - Adequate dyspnea and symptom management
  - Reduction of patient/family distress
  - Acceptable sense of control
  - Relief of caregiver burden
  - Strengthened relationships
  - Optimized quality of life
  - Personal growth and enhanced meaning

  - Continue to treat and monitor symptoms and quality of life

- **Unacceptable**
  - Intensify palliative care interventions
  - Consult or refer to specialized palliative care services or hospice

  - Ongoing reassessment

---

*For acute progressive dyspnea, more aggressive titration may be required.*

**PAL-11**
### DYSPNEA

<table>
<thead>
<tr>
<th>ESTIMATED LIFE EXPECTANCY</th>
<th>INTERVENTIONS</th>
<th>REASSESSMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td>Years</td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
| Year to months           | • Assess symptom intensity | Acceptable:  
|                          |   • Use labored breathing or other physical signs of dyspnea in noncommunicative patients |   • Adequate dyspnea and symptom management |
|                          |   • Focus on comfort |   • Reduction of patient/family distress |
|                          |   • Continue to treat underlying condition as appropriate |   • Acceptable sense of control |
|                          |   • Relieve symptoms |   • Relief of caregiver burden |
|                          |   • Fans |   • Strengthened relationships |
|                          |   • Oxygen if hypoxic and/or subjective relief is reported |   • Optimized quality of life |
|                          |   • Nonpharmacologic therapies; educational, psychosocial, and emotional support (See PAL-11) |   • Personal growth and enhanced meaning |
|                          |   • If fluid overload is a contributing factor: | Continue to treat and monitor symptoms and quality of life |
|                          |     • Decrease/discontinue enteral or parenteral fluid | Ongoing reassessment |
|                          |     • Consider low-dose diuretics | |
|                          |     • If opioid naive, morphine, 2.5–10 mg PO q 2 hr pm or 1–3 mg IV q 2 hr pm⁹ | |
|                          |     • If on chronic opioids, consider increasing dose by 25% | |
|                          |     • Benzodiazepines (if benzodiazepine naive, lorazepam, 0.5–1 mg PO q 4 hr pm) | |
|                          |     • Reduce excessive secretions⁶ with scopolamine, 0.4 mg subcut q 4 hr pm; 1.5 mg patches, 1–3 patches q 3 d; OR atropine 1% ophthalmic solution 1–2 drops SL q 4 hr pm; OR glycopyrrolate 0.2–0.4 mg IV or subcut q 4 hr pm | |
|                          |     • Consider time-limited trial of mechanical ventilation as indicated | |
|                          |     • Address patient and family preferences, prognosis, and reversibility of respiratory failure | |
|                          |     • Provide sedation as needed | |
|                          |     • Provide anticipatory guidance for patient/family regarding dying of respiratory failure | |
|                          |     • Provide emotional and spiritual support | |
| Months to weeks           |               |              |
| Weeks to days (Dying patient) |               | Unacceptable |
|                           |               |               |

---

⁹For acute progressive dyspnea, more aggressive titration may be required.


³Available online, in these guidelines, at NCCN.org.
### ANOREXIA/CACHEXIA

**ESTIMATED LIFE EXPECTANCY**

<table>
<thead>
<tr>
<th>Years</th>
<th>Year to months</th>
<th>Months to weeks</th>
<th>Weeks to days (Dying patient)</th>
</tr>
</thead>
</table>

- Evaluate rate/severity of weight loss
- Treat reversible cause of anorexia:
  - Oral-pharyngeal candidiasis
  - Depression/anorexia (Mirtazapine 7.5–30 mg hs)
- Symptoms that interfere with intake
  - Dysgeusia
  - Xerostomia
  - Mucositis
- Early satiety (if gastroparesis: try metoclopramide)
- NV
- Dyspnea
- Constipation
- Pain
- Fatigue
- Eating disorders/body image
- Review/modify medications that interfere with intake
- Evaluate for endocrine abnormalities:
  - Hypogonadism
  - Thyroid dysfunction
  - Metabolic abnormalities (eg, increased calcium)
- Consider an exercise program
- Assess social and economic factors
- Consider nutrition consult
- Consider nutrition support, enteral and parenteral feeding (as appropriate)

**INTERVENTIONS**

**REASSESSMENT**

**Acceptable:**
- Weight stabilization or gain
- Improvement in symptoms that interfere with intake
- Improved energy
- Resolution of metabolic or endocrine abnormalities

**Unacceptable:**
- Intensify palliative care interventions
- Provide dietary consultation
- Consider clinical trial

**Continue to treat and monitor symptoms and quality of life**

**Ongoing reassessment**

---

**Clinical trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.
ANOREXIA/CACHEXIA

ESTIMATED LIFE EXPECTANCY

YEARS

Year to months

MONTHS TO WEEKS

Weeks to days (Dying patient)

INTERVENTIONS

See Interventions (PAL-13)

• Assess meaning of symptoms of anorexia and cachexia to patient and family
• Consider appetite stimulant
  › Megestrol acetate, 400–800 mg/d
  › Olanzapine 5 mg/d
  › Dexamethasone 2–8 mg/d
• Consider cannabinoid
• Focus on patient goals and preferences
• Provide family with alternate ways of caring for the patient
• Provide emotional support
• Treat for depression, if appropriate (mirtazapine 7.5–30 mg hs)
• Provide education and support to patient and family regarding emotional aspects of withdrawal of nutritional support.
• Inform patient and family of natural history of disease, including the following points:
  › Absence of hunger and thirst is normal in the dying patient
  › Nutritional support may not be metabolized in patients with advanced cancer
  › There are risks associated with artificial nutrition and hydration, including fluid overload, infection, and hastened death
  › Symptoms like dry mouth should be treated with local measures (eg, mouth care, small amounts of liquids)
• Withholding or withdrawing nutrition is ethically permissible and may improve some symptoms.

REASSESSMENT

Acceptable:
• Adequate anorexia/cachexia symptom management
• Reduction of patient/family distress
• Acceptable sense of control
• Relief of caregiver burden
• Strengthened relationships
• Optimized quality of life
• Personal growth and enhanced meaning

Ongoing reassessment

Continue to treat and monitor symptoms and quality of life

Unacceptable

• Intensify palliative care interventions
• Consult or refer to specialized palliative care services or hospice


Version 1.2016, 11-17-15 ©2015 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
### Palliative Care, Version 1.2016

**Clinical trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

---

**Palliative Care, Version 1.2016**

**Clinical trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

---

**NAUSEA AND VOMITING**

**ESTIMATED LIFE EXPECTANCY**

<table>
<thead>
<tr>
<th>Years</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Chemotherapy/radiation therapy-induced (See NCCN Guidelines for Antiemesis*)</td>
</tr>
<tr>
<td>• Severe constipation/fecal impaction (See PAL-17)</td>
</tr>
<tr>
<td>• Gastroparesis (metoclopramide, 5–10 mg PO QID 30 min before meals and at bedtime)</td>
</tr>
<tr>
<td>• Bowel obstruction (See PAL-20)</td>
</tr>
<tr>
<td>• Central nervous system (CNS) involvement</td>
</tr>
<tr>
<td>• Corticosteroids (dexamethasone, 4–8 mg BID-TID)</td>
</tr>
<tr>
<td>• Palliative radiation therapy</td>
</tr>
<tr>
<td>• Gastric outlet obstruction from intra-abdominal tumor or liver metastasis</td>
</tr>
<tr>
<td>• Consider treatment with corticosteroids, a proton pump inhibitor, and metoclopramide</td>
</tr>
<tr>
<td>• Endoscopic stenting</td>
</tr>
<tr>
<td>• Decompressing G-Tube</td>
</tr>
<tr>
<td>• Gastritis/GERD</td>
</tr>
<tr>
<td>• Proton pump inhibitor</td>
</tr>
<tr>
<td>• H2-blocker</td>
</tr>
<tr>
<td>• Metabolic abnormalities</td>
</tr>
<tr>
<td>• Hypercalcemia</td>
</tr>
<tr>
<td>• Uremia</td>
</tr>
<tr>
<td>• Dehydration</td>
</tr>
</tbody>
</table>

**INTERVENTIONS**

- Discontinue any unnecessary medications
- Check available blood levels of necessary medications (eg, digoxin, phenytoin, carbamazepine, tricyclic antidepressants)
- Treat medication-induced gastropathy (eg, proton pump inhibitor, metoclopramide)
- Consider rotating and/or reducing opioid requirement with non-nauseating coanalgesics or procedural interventions
- Psychogenic
  - Consider psychiatric consultation if patient has an eating disorder, somatization, phobia, or panic disorder causing NV. See NCCN Guidelines for Distress Management*
- Non-specific NV
  - Initiate pharmacologic management with dopamine receptor antagonists (eg, haloperidol, metoclopramide, prochlorperazine, olanzapine)
  - If anxiety contributes to NV, consider adding lorazepam, 0.5–1 mg q 4 hr prn
  - If oral route is not feasible, consider sublingual, rectal, subcutaneous, or intravenous administration of anti-nausea therapy
  - Consider non-pharmacologic therapies, such as acupuncture, hypnosis, and cognitive behavioral therapy
  - Consider cannabinoid

**PA L-15**

If NV persists:

- Add a 5-HT3 antagonist (eg, ondansetron) ± anticholinergic agent (eg, scopolamine) ± cannabinoid

- Consider using a continuous IV/subcut infusion of antiemetics; consider an opioid rotation if patient is on opioids.

**PA L-16**

- If NV stops: See Reassessment (PAL-16)

**PA L-33†**

- If NV persists:
  - Consider intensive palliative care interventions
  - Consult or refer to specialized palliative care services or hospice
  - Consider palliative sedation (See PAL-33†)

**PAL-17**

If NV stops:

- See Reassessment (PAL-16)

**Ongoing reassessment**

(See Interventions, PAL-15)

---

*To view the most recent version of these guidelines, visit NCCN.org.

---

In patients with advanced cancer, NV may be secondary to the cachexia syndrome (chronic nausea, anorexia, asthenia, changing body image, and autonomic failure).

An around-the-clock dosing schedule may provide the most consistent benefit to the patient.

Continuous intravenous or subcutaneous infusions of different antiemetics may be necessary for the management of intractable NV.
PERSISTENT NAUSEA AND VOMITING

INTERVENTIONS

| Titrate dopamine receptor antagonist (eg, prochlorperazine, haloperidol, metoclopramide, olanzapine) to maximum benefit and tolerance. |
| If NV persists: |
| Add a 5-HT3 antagonist (eg, ondansetron) ± anticholinergic agent (eg, scopolamine) ± antihistamine (eg, meclizine) ± cannabinoïd. |
| If NV persists: |
| Add a corticosteroid (eg, dexamethasone) ± olanzapine, if not already tried. |
| If NV persists: |
| Consider using a continuous IV/subcut infusion of antiemetics; consider an opioid rotation if patient is on opioids. |

REASSESSMENT

| Acceptable: |
| • Adequate NV symptom management |
| • Reduction of patient/family distress |
| • Acceptable sense of control |
| • Relief of caregiver burden |
| • Strengthened relationships |
| • Optimized quality of life |
| Continue to treat and monitor symptoms and quality of life |
| Unacceptable |
| • Intensify palliative care interventions |
| • Consult or refer to specialized palliative care services or hospice |
| • Consider palliative sedation (See PAL-33†) |
| Ongoing reassessment (See Interventions, PAL-15) |

†Available online, in these guidelines, at NCCN.org.
### Constipation

<table>
<thead>
<tr>
<th>Preventive measures</th>
<th>Interventions</th>
<th>Reassessment</th>
</tr>
</thead>
<tbody>
<tr>
<td>• Increase fluids</td>
<td>If constipation is present:</td>
<td>Acceptable:</td>
</tr>
<tr>
<td>• Increase dietary fiber if patient has</td>
<td>• Assess for cause and severity of constipation</td>
<td>• Adequate constipation symptom management</td>
</tr>
<tr>
<td>adequate fluid intake and physical activity</td>
<td>• Discontinue any non-essential constipating medication</td>
<td>• Reduction of patient/family distress</td>
</tr>
<tr>
<td>• Exercise, if appropriate</td>
<td>• Rule out impaction, especially if diarrhea accompanies constipation (overflow around impaction)</td>
<td>• Acceptable sense of control</td>
</tr>
<tr>
<td>• Administer prophylactic medications</td>
<td>• Rule out obstruction (physical exam, abdominal x-ray/consider GI consult)</td>
<td>• Relief of caregiver burden</td>
</tr>
<tr>
<td>• Stimulant laxative ± stool softener (senna ± docusate, 2 tablets every night)</td>
<td>• Treat other causes (eg, hypercalcemia, hypokalemia, hypothyroidism, diabetes mellitus, medications)</td>
<td>• Strengthened relationships</td>
</tr>
<tr>
<td>• Increase dose of laxative ± stool softener (senna ± docusate, 2–3 tablets BID-TID) with goal of 1 non-forced BM every 1–2 days</td>
<td>• Add and titrate bisacodyl 10–15 mg daily-TID with a goal of 1 non-forced bowel movement (BM) every 1–2 days if impacted:</td>
<td>• Optimized quality of life</td>
</tr>
<tr>
<td></td>
<td>• Administer glycerine suppository ± mineral oil retention enema</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Perform manual disimpaction following pre-medication with analgesic ± anxiolytic</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Reassess for cause and severity of constipation</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Recheck for impaction or obstruction</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Consider adding other laxatives, such as bisacodyl suppository (one rectally daily-BID); polyethylene glycol (1 capful/8 oz water BID); lactulose, 30–60 mL BID-QID; sorbitol, 30 mL every 2 h x 3, then prn; magnesium hydroxide, 30–60 mL daily-BID; or magnesium citrate, 8 oz daily</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Consider methylnaltrexone for opioid-induced constipation, except for post-op ileus and mechanical bowel obstruction, 0.15 mg/kg SC subcut every other day, no more than once a day</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Tap water enema until clear</td>
<td></td>
</tr>
<tr>
<td></td>
<td>• Consider use of a prokinetic agent (eg, metoclopramide, 10–20 mg PO QID)</td>
<td></td>
</tr>
</tbody>
</table>

#### Preventive Measures
- Increase fluids
- Increase dietary fiber if patient has adequate fluid intake and physical activity
- Exercise, if appropriate
- Administer prophylactic medications
  - Stimulant laxative ± stool softener (senna ± docusate, 2 tablets every night)
  - Increase dose of laxative ± stool softener (senna ± docusate, 2–3 tablets BID-TID) with goal of 1 non-forced BM every 1–2 days

#### Reassessment
- Continue to treat and monitor symptoms and quality of life
- Intensify palliative care interventions
- Consult or refer to specialized palliative care services or hospice

#### Ongoing Reassessment

---

**Clinical trials:** NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.
### Palliative Care, Version 1.2016

#### DIARRHEA

<table>
<thead>
<tr>
<th>ESTIMATED LIFE EXPECTANCY</th>
<th>SCREENING</th>
<th>ASSESSMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td>Determine Diarrhea Grade (Increase over Baseline)</td>
<td>Provide immediate antidiarrheal therapy indicated by grade.</td>
</tr>
<tr>
<td></td>
<td>• Grade 1: Increase of &lt;4 stools/day over baseline; mild increase in ostomy output compared with baseline</td>
<td>• If chemotherapy induced, decrease or delay the next dose of chemotherapy</td>
</tr>
<tr>
<td></td>
<td>• Grade 2: Increase of 4–6 stools/day over baseline; moderate increase in ostomy output compared with baseline</td>
<td>Assess for Cause:</td>
</tr>
<tr>
<td></td>
<td>• Grade 3: Increase of &gt;7 stools/day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared with baseline; limiting self-care; Interferes with ADL</td>
<td>• Recent antibiotic use</td>
</tr>
<tr>
<td></td>
<td>• Grade 4: Life-threatening consequences urgent intervention indicated</td>
<td>• Drugs that frequently induce diarrhea</td>
</tr>
</tbody>
</table>

#### CONSIDERATIONS

- **Screening**: Determine Diarrhea Grade (Increase over Baseline)
- **Assessment**: Provide immediate antidiarrheal therapy indicated by grade.
- **Grade 1**: Increase of <4 stools/day over baseline; mild increase in ostomy output compared with baseline
- **Grade 2**: Increase of 4–6 stools/day over baseline; moderate increase in ostomy output compared with baseline
- **Grade 3**: Increase of >7 stools/day over baseline; incontinence; hospitalization indicated; severe increase in ostomy output compared with baseline; limiting self-care; Interferes with ADL
- **Grade 4**: Life-threatening consequences urgent intervention indicated

#### REASSESSMENT

- Consult or refer to services or hospice specialized care interventions.
- Intensify palliative care interventions.
- Continue to treat and manage symptoms.

#### REFERENCES

- MNCI Table 3: http://www.cancer.gov/cancertopics/pdq/supportivecare/gastrointestinalcomplications/HealthProfessional/page5#section_5.8

---

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 14 Number 1 | January 2016

©2015 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.

Version 1.2016, 11-17-15 ©2015 National Comprehensive Cancer Network, Inc. All rights reserved. The NCCN Guidelines® and this illustration may not be reproduced in any form without the express written permission of NCCN®.
### Palliative Care, Version 1.2016

#### Clinical trials
NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.

---

<table>
<thead>
<tr>
<th>ESTIMATED LIFE EXPECTANCY</th>
<th>SCREENING</th>
<th>INTERVENTION</th>
</tr>
</thead>
<tbody>
<tr>
<td>Years</td>
<td>GRADE 1</td>
<td>- Provide oral hydration and electrolyte replacement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Initiate antidiarrheal:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Loperamide 4 mg PO x 1, then 2 mg PO after each loose stool, up to 16 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- If patient not already on opioids:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Diphenoxylate/atropine 1–2 tabs PO q 6 hr PRN, Maximum 8 tabs/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Bland/BRAT diet (Bananas, Rice, Applesauce, Toast)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Continue oral hydration and electrolyte replacement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- If chemotherapy-induced:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Decrease dose or discontinue chemotherapy</td>
</tr>
<tr>
<td>Year to months</td>
<td>GRADE 2</td>
<td>- Provide IV fluids if patient is unable to tolerate oral fluids</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Initiate/continue antidiarrheal--as above</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Bland/BRAT diet (Bananas, Rice, Applesauce, Toast)</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Continue oral hydration and electrolyte replacement</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Consider anticholinergic agents</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Hyoscyamine 0.125 mg PO/ODT/SL q 4 hr PRN, Max: 1.5 mg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Atropine 0.5–1 mg subcut; IM; IV; SL q 4–6 hr prn</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- If infection-induced (C. diff):</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Metronidazole 500 mg PO/IV QID x 10–14 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Vancomycin 125–500 mg PO QID x 10–14 days</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- If infection-induced and not C. diff:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Treat with appropriate antibiotics</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- If chemotherapy-induced:</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Delay or discontinue chemotherapy</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- If ipilimumab-related diarrhea, consider</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Corticosteroids for 0.1–1 mg/kg/day</td>
</tr>
<tr>
<td></td>
<td></td>
<td>- Infliximab 5 mg/kg q 2–6 weeks</td>
</tr>
<tr>
<td>Persistent Grades 2, 3, 4</td>
<td>Inpatient hospitalization (intensive care for Grade 4)</td>
<td></td>
</tr>
<tr>
<td>Weeks to days</td>
<td></td>
<td>- Provide IV fluids and use antidiarrheal agents and anticholinergics as mentioned above</td>
</tr>
<tr>
<td>(Dying patient)</td>
<td></td>
<td>- Consider Octreotide 100–500 mcg/day subcut or IV, q 8 hr or by continuous infusion</td>
</tr>
</tbody>
</table>

---

**PAL-19**

---

Clinical trials: NCCN believes that the best management of any cancer patient is in a clinical trial. Participation in clinical trials is especially encouraged. All recommendations are category 2A unless otherwise indicated.
**Palliative Care, Version 1.2016**

### MALIGNANT BOWEL OBSTRUCTION

<table>
<thead>
<tr>
<th>ESTIMATED LIFE EXPECTANCY</th>
<th>ASSESSMENT</th>
</tr>
</thead>
<tbody>
<tr>
<td><strong>Years</strong></td>
<td></td>
</tr>
<tr>
<td>Year to months</td>
<td></td>
</tr>
<tr>
<td>Months to weeks</td>
<td></td>
</tr>
<tr>
<td><strong>Weeks to days (Dying patient)</strong></td>
<td></td>
</tr>
</tbody>
</table>

- Screen for and treat underlying reversible causes
  - Adhesions
  - Radiation-induced strictures
  - Internal hernias
- Assess for malignant causes
  - Tumor mass
  - Carcinomatosis
- Assess the goals of treatment for the patient, which can help guide the intervention
  - (e.g., decrease NV, allow patient to eat, decrease pain, allow patient to go home/to hospice)

**See Interventions (PAL-21)**

- Consider medical management rather than surgical management
- Assess the goals of treatment for the patient, which can help guide the intervention
  - (e.g., decrease NV, allow patient to eat, decrease pain, allow patient to go home/to hospice)
- Provide education and support to patient and family

<table>
<thead>
<tr>
<th><strong>Pharmacologic management</strong></th>
<th><strong>See Reassessment (PAL-21)</strong></th>
</tr>
</thead>
<tbody>
<tr>
<td>- Intravenous or subcutaneous fluids</td>
<td></td>
</tr>
<tr>
<td>- Enteral tube drainage</td>
<td></td>
</tr>
<tr>
<td>- Consider only if other measures fail to reduce vomiting</td>
<td></td>
</tr>
<tr>
<td>- Endoscopic management</td>
<td></td>
</tr>
</tbody>
</table>

**Notes:****

- Plain film radiography may be helpful in confirming the clinical diagnosis of bowel obstruction. Consider a computed tomography scan if surgical intervention is contemplated, as it is more sensitive and may help identify the cause of obstruction.

- Most malignant bowel obstructions are partial, allowing time to discuss appropriate intervention with the patient and family.
**Palliative Care, Version 1.2016**

### MALIGNANT BOWEL OBSTRUCTION

**INTERVENTIONS**

- Operative management
  - Risks must be discussed with the patient/family
  - Improved quality of life should be the primary goal of surgical treatment
- Endoscopic management
  - Percutaneous endoscopic gastrostomy tube for drainage
  - Endoscopic stent placement
- Interventional radiology management
  - Ultrasound-guided gastrostomy tube for drainage
- Pharmacologic management when the goal is maintaining gut function:
  - Use rectal, transdermal, subcutaneous, or intravenous routes of administration
  - Antiemetics: Do not use antiemetics that increase gastrointestinal mobility such as metoclopramide; however, these may be beneficial in incomplete bowel obstruction
  - Corticosteroids: Dexamethasone 4–12 mg IV, daily, discontinue if no improvement in 3–5 days
- Pharmacologic management when gut function cannot be maintained:
  - Administer anticholinergics (eg, scopolamine, hyoscyamine, glycopyrrolate)
  - Administer octreotide: (100–300 mcg SC BID-TID or 10–40 mcg/hr continuous SC/IV infusion) if prognosis >8 weeks, consider long acting release (LAR) or depot injection
  - Intravenous or subcutaneous fluids
    - Consider if there is evidence of dehydration
  - Nasogastric or gastric tube drainage
    - Usually uncomfortable
    - Increased risk of aspiration
    - Consider a limited trial only if other measures fail to reduce vomiting
  - Total parenteral nutrition (TPN)
    - Consider only if there is expected improvement of quality of life and life expectancy of months to years

### REASSESSMENT

- **Acceptable:**
  - Adequate management of malignant bowel obstruction symptoms
  - Reduction of patient/family distress
  - Acceptable sense of control
  - Relief of caregiver burden
  - Strengthened relationships
  - Optimized quality of life
  - Personal growth and enhanced meaning

- **Unacceptable:**

**Ongoing reassessment (See PAL-21)**

<table>
<thead>
<tr>
<th>PAL-21</th>
</tr>
</thead>
</table>

**Discuss risk of mortality, morbidity, and re-obstruction. Risk factors for poor surgical outcome include: ascites, carcinomatosis, palpable intraabdominal masses, multiple bowel obstructions, previous abdominal radiation, very advanced disease, and poor overall clinical status.**
### SLEEP/WAKE DISTURBANCES INCLUDING INSOMNIA AND SEDATION

#### ESTIMATED LIFE EXPECTANCY

<table>
<thead>
<tr>
<th>Years</th>
<th>Month to months</th>
<th>Months to weeks</th>
<th>Weeks to days (Dying patient)</th>
</tr>
</thead>
<tbody>
<tr>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

#### INTERVENTIONS
- Evaluate type/severity of sleep-wake disturbance, including daytime impairments (eg, Epworth Sleepiness Scale)
- Explore fears and anxiety regarding death/disease
- Provide sleep-hygiene education
- Provide cognitive-behavioral treatment
  - Includes stimulus control, progressive muscle relaxation
- Consider polysomnography if history is suggestive of sleep-disordered breathing
- Treat contributing factors:
  - Pain, depression, anxiety, delirium, and nausea
  - Medication side effects or withdrawal syndromes (eg, corticosteroids, opioids, anticonvulsants, caffeine, hormones, herbs, barbiturates, benzodiazepines, alcohol, tricyclic antidepressants)
  - Primary sleep disorders such as obstructive sleep apnea and periodic limb movement disorder
- For restless leg syndrome consider trial of the following:
  - Ropinirole
  - Pramipexole with pregabaline
  - Carbidopa-levodopa
- Provide pharmacologic therapies for refractory sleep/wake disturbance
  - Insomnia:
    - Trazodone, 25–100 mg PO at bedtime
    - Olanzapine, 2.5–5 mg PO at bedtime
    - Zolpidem, 5 mg PO at bedtime
    - Mirtazapine, 7.5–30 mg PO at bedtime
    - Chlorpromazine, 25–50 mg PO at bedtime
    - Quetiapine, 2.5–5 mg PO at bedtime
    - Lorazepam, 0.5–1 mg PO at bedtime
  - Daytime sedation:
    - Caffeine 100–200 mg PO q 6 hrs, last dose 4 PM
    - Methylphenidate, start with 2.5–20 mg PO BID, second dose no later than 6 hours before bedtime
    - Dextroamphetamine, 2.5–10 mg PO BID, second dose no later than 12 hours before bedtime
    - Modafinil, 100–400 mg PO each morning
- Assess patient’s desire to have insomnia and sedation treated
- Adjust doses of pharmacologic therapies
  - Consider clonazepam, 25–100 mg PO/PR at bedtime

#### REASSESSMENT

- Acceptable:
  - Adequate management of symptoms
  - Reduction of patient/family distress
  - Acceptable sense of control
  - Relief of caregiver burden
  - Strengthened relationships
  - Optimized quality of life
  - Personal growth and enhanced meaning

- Unacceptable

- Continue to treat and monitor symptoms and quality of life

- Re-evaluate contributing etiologies
- Change insomnia or antisedation therapy
- Intensify palliative care interventions
- Consult or refer to specialized palliative care services or hospice
- Consider referral for polysomnography
Assessment by their primary oncology team, evaluating the benefits and burdens of anticancer therapy; physical symptoms; psychosocial or spiritual distress; personal goals, values, and expectations; educational and informational needs; and cultural factors affecting care.1–3

Assessment for Benefits and Burdens of Anticancer Therapy
Many cancer symptoms can be relieved by controlling the cancer with anti-cancer therapy. Assessment of the benefits and burdens of anticancer therapy for each individual is based on the existing NCCN disease-specific guidelines (the most recent version of all guidelines can be found on the NCCN Web site at NCCN.org). Special attention should be given to the natural history of the specific tumor; the potential for response to further treatment; the meaning of anticancer therapy to the patient and family; the potential for treatment-related toxicities, including impairment of vital organs and performance status; and serious comorbid conditions. Specific recommendations regarding anticancer therapy for patients with various life expectancies are discussed in Palliative Care Interventions (see next column).

Assessment of Personal Goals, Values, and Expectations
Patients and families should also be asked about personal goals, values, and expectations. Their priorities for palliative care, including their goals and the perceived meaning of anticancer therapy and the importance they place on quality of life, should be assessed. Goals and expectations that might be better met by the hospice model of palliative care should be identified. When appropriate, it is important to determine the patient’s understanding of the incurability of their disease and whether patients wish to know survival statistics.

Assessment of Physical Symptoms
The most common symptoms that need to be assessed are pain, dyspnea, anorexia, cachexia, nausea, vomiting, constipation, malignant bowel obstruction, fatigue, weakness, asthenia, insomnia, daytime sedation, and delirium.4 Palliative interventions for these symptoms are discussed individually in subsequent sections.

Assessment of Psychosocial Distress
Assessment of psychosocial distress should focus on illness-related distress and psychosocial, spiritual, or existential issues according to the NCCN Guidelines for Distress Management (available at NCCN.org). Special problems with social support and resources (ie, home, family, community, or financial issues) must also be assessed. Recommendations for the management of psychosocial distress can be found in subsequent sections and in the NCCN Guidelines for Distress Management (available at NCCN.org).

Assessment of Educational and Informational Needs and Cultural Factors Affecting Care
The values and preferences of patients and families about information and communication should also be assessed. The oncology team should inquire about cultural factors affecting care and perceptions of the patient/family regarding the patient’s disease status.

Palliative Care Interventions
The oncology team should start palliative treatments following the specific recommendations described in these guidelines for common symptoms. Comorbid physical and psychosocial conditions should be treated by appropriate clinicians. Consultation or collaboration with palliative care specialists or teams is recommended for patients with more complex problems to improve their quality of life and survival.5,6 Referrals should be made as needed to mental health and social services, pastoral care, health care interpreters, hospice services, or other specialists. Finally, the oncology team can be helpful in mobilizing community support through religious organizations, schools, or community agencies.

The panel divided patients into 3 groups to address the effect of life expectancy on the delivery of palliative care interventions: 1) patients with years to months to live; 2) patients with months to weeks to live; and 3) dying patients in their final weeks to days. Patients in their final hours of life are referred to as “imminently dying” and may require special interventions. The panel recognizes the lack of precision in estimating life expectancy but believes that this delineation will be useful for the delivery of appropriate palliative care interventions. The patient and family’s personal, spiritual and existential, cultural, and religious goals, values, and expectations may change throughout these timeframes. Optimal provision of palliative care requires ongoing reassessment and modification of strategies, as well as ongoing communication between the patient, family, and health care team.
Indicators that patients are in their last 6 months of life include decreased performance status (ECOG score ≥3; Karnofsky Performance Score ≤50), persistent hypercalcemia, central nervous system metastases, delirium, superior vena cava syndrome, spinal cord compression, cachexia, malignant effusions, liver failure, kidney failure, or other serious comorbid conditions. Many patients with stage IV cancers, especially those with metastatic lung cancer, pancreatic cancer, and glioblastoma multiforme, would benefit from palliative care beginning at diagnosis, because expected survival is limited.\textsuperscript{7–9}

**Anticancer Therapy**

A recent Institute of Medicine (IOM) report, “Communicating with Patients on Health Care Evidence,” found that 90% of Americans surveyed want to know their options for tests and treatments and to be involved in decision-making for their health, with almost 50% wanting to discuss the option of doing nothing.\textsuperscript{10,11} However, the report also found that far fewer respondents had such discussions with their physicians.

Patients who have years to months to live and a good performance status are likely to be interested in continuing anticancer therapy to prolong survival and reduce cancer-related symptoms.\textsuperscript{12–15} Anticancer therapy may be conventional evidence-based treatment as outlined in the NCCN disease-specific guidelines (available at NCCN.org) or treatment in the context of a clinical trial. In some of the advanced-stage cancers, chemotherapy may be superior to best supportive care and may prolong survival.\textsuperscript{16,17} Furthermore, patients with advanced non-small cell lung cancer who are not eligible for systemic chemotherapy may benefit from targeted therapies that are effective for relieving symptoms, maintaining stable disease, and improving quality of life without the adverse events that may be associated with cytotoxic cancer therapies.\textsuperscript{18} Physicians, patients, and their families should discuss intent, goals, and range of choices; benefits and burdens of anticancer therapy; and possible effects on quality of life. In addition, the oncology team should prepare the patient psychologically for possible disease progression.

Anticancer therapy may at times go beyond what is evidence-based. Interestingly, data from a CanCORS study of 1574 patients with metastatic non-small cell lung cancer suggested that many patients received higher doses and a greater number of palliative radiation treatments than is supported by current evidence.\textsuperscript{19} Additionally, a study of patients with metastatic colorectal cancer revealed that more than 90\% of patients consulted with a medical oncologist, and 82\% of these patients received chemotherapy.\textsuperscript{20}

Patients with months to weeks to live should be provided with guidance regarding the anticipated course of the disease. Physicians should confirm patient understanding of goals of therapy and preferences regarding prognostic information. Patients at this point are typically tired of therapy, homebound, and concerned about the side effects of more treatment. The focus of treatment for these patients shifts from prolonging life toward maintaining quality of life. These patients should consider potential discontinuation of anticancer treatment and be offered best supportive care, including referral to palliative care or hospice.\textsuperscript{21,22} To avoid demeaning the value of end-of-life care, palliative care and/or hospice care should not be described as “giving up,” but instead reframed as “fighting” for better quality of life.

In general, patients with weeks to days to live (ie, dying patients) should not be given anticancer therapy but should be given intensive palliative care focusing on symptom management and preparation for the dying process.

**Symptom Management**

Special considerations in the implementation of these guidelines based on life expectancy are delineated in the algorithms (see page 84). The major focus of these special considerations is the withholding and withdrawal of aggressive interventions; prevention and elimination of side effects associated with pharmacologic pain management; the acceptance of loss of function for the sake of relief of symptoms; and the treatment of the unique symptoms of patients in their final hours of life.

With regard to symptoms, the management of pain, dyspnea, anorexia/cachexia, nausea and vomiting, constipation, diarrhea, malignant bowel obstruction, fatigue, delirium, and psychologic distress is fundamental.\textsuperscript{23–25} These symptoms are discussed in detail in subsequent sections. As a general principle, if/when appropriate, providers should try to use palliative interventions that may address multiple symptoms.

**Pain:** See the NCCN Guidelines for Adult Cancer Pain (available online at NCCN.org) for more de-
Palliative Care, Version 1.2016

tail. In addition, it is important to note that dying patients in their last weeks of life have several specific requirements. For instance, opioid dose should not be reduced solely for decreased blood pressure, respiration rate, or level of consciousness when opioid is necessary for adequate management of dyspnea and pain. In fact, opioids can be titrated aggressively for moderate/severe acute/chronic pain. In addition, palliative sedation can be considered for refractory pain (see next section) after consultation with pain management/palliative care specialists.

**Dyspnea:** Dyspnea is one of the most common symptoms in patients with advanced lung cancer. The American Thoracic Society consensus statement defines dyspnea as “a subjective experience of breathing discomfort that consists of qualitatively distinct sensations that vary in intensity.”

Symptom intensity should first be assessed in all patients. Symptom intensity in noncommunicative patients with weeks to days to live should be assessed using physical signs of dyspnea. Underlying causes or comorbid conditions should then be treated using chemotherapy or radiation therapy; therapeutic procedures for cardiac, pleural, or abdominal fluid; bronchoscopic therapy; or bronchodilators, diuretics, steroids, antibiotics, transfusions, or anticoagulants for pulmonary emboli.

Both pharmacologic and nonpharmacologic interventions have been investigated in the management of dyspnea. A recent review concluded that little definitive data evaluating the effectiveness of dyspnea interventions exist and that randomized controlled trials are needed. Other reviews have determined that there are sufficient data to make treatment recommendations. Pharmacologic interventions may include opioids with or without benzodiazepines. Benzodiazepines can be tried for treatment of dyspnea if it is associated with anxiety; the beneficial effect of benzodiazepines on dyspnea in patients with advanced cancer is small.

Of the opioids, morphine has undergone the most extensive investigation for treating dyspnea in patients with cancer, but recent studies have also looked at opioids such as fentanyl and oxycodone. A single-institution trial of nebulized fentanyl in patients with cancer showed improved oxygenation and reduced tachypnea, and 79% of patients said it improved their breathing. An attempted randomized, placebo-controlled trial at the same institution was not successful, because the practice had already diffused widely, with more than 1000 doses being prescribed.

Multiple case reports show promising data about fentanyl, but further research is needed. In a small, randomized controlled trial, prophylactic subcutaneous fentanyl was effective for improving dyspnea and fatigue at rest and after a 6-minute walk test. A study revealed that nebulized fentanyl reduced intensity and unpleasantness of dyspnea in patients with chronic obstructive pulmonary disease (COPD). Nebulized fentanyl has not yet been studied in patients with cancer, but it can be considered in patients who do not respond well to the other interventions in these guidelines. Additionally, an observational study of 136 patients with terminal cancer also suggested that continuous infusion of subcutaneous oxycodone may provide relief of dyspnea in addition to relief of pain. For patients receiving chronic opioids, the panel recommends consideration of a 25% dose increase to manage dyspnea.

Scopolamine, atropine, hyoscineamine, and glycopyrrolate are options to reduce excessive secretions associated with dyspnea. Glycopyrrolate does not effectively cross the blood brain barrier and is less likely than the other drug options to cause delirium, but this agent can produce anticholinergic side effects. Scopolamine can be administered subcutaneously or transdermally; physicians should be aware that the onset of benefit for transdermal scopolamine patches is about 12 hours, and they are thus not an appropriate choice for imminently dying patients. A subcutaneous injection of scopolamine can be administered when the patch is applied or if management of secretions is inadequate.

Nonpharmacologic interventions include the use of handheld fans directed at the face, supplemental oxygen, and mechanical ventilation. A randomized, controlled, crossover trial demonstrated that breathlessness was reduced in patients when they directed a handheld fan toward their faces. Another randomized controlled trial examined the effects of room air versus palliative oxygen delivered via nasal cannula in patients with refractory dyspnea. Dyspnea scores were no different among patients receiving palliative oxygen versus room air, encouraging the use of less burdensome interventions. In a recent feasibility study of 200 patients with solid tumors randomized to receive either noninvasive positive-pressure ven-
Anorexia/Cachexia

Cachexia is physical wasting with loss of skeletal and visceral muscle mass and is very common among patients with cancer.\(^{59,60}\) Many patients with cancer lose the desire to eat (anorexia), which contributes to cachexia. Cachexia can also occur independently from anorexia, as proinflammatory cytokines and tumor-derived factors directly lead to muscle proteolysis.\(^{59,60}\) Cachexia leads to asthenia (weakness), hypoalbuminemia, emaciation, immune system impairment, metabolic dysfunction, and autonomic failure. Cancer-related cachexia has also been associated with failure of anticancer treatment, increased treatment toxicity, delayed treatment initiation, early treatment termination, shorter survival, and psychosocial distress.\(^ {59,61}\) A recent study that examined cancer cachexia in a cohort of 1473 patients across all weight ranges showed that muscle depletion conveys a similarly poor prognosis as involuntary weight loss, regardless of body mass index.\(^ {62}\)

Reversible causes of anorexia, such as oropharyngeal candidiasis and depression, should be addressed. Treatment includes the relief of symptoms that interfere with food intake (eg, pain, constipation, nausea/vomiting), as well as metoclopramide for early satiety.\(^ {30,33}\)

For patients with months-to-weeks or weeks-to-days life expectancy, consider the use of appetite stimulants (eg, megestrol acetate, dexamethasone, olanzapine) if increased appetite is an important aspect of quality of life.\(^ {63-67}\) A recent systematic review and meta-analysis of megestrol acetate revealed improved appetite and slight improvements in weight gain when using this drug to treat anorexia/cachexia in patients with cancer.\(^ {64}\) Although 1 of 4 patients treated with megestrol acetate will have an increase in appetite and 1 of 12 will have an increase in weight, clinicians need to know that 1 of 6 will develop thrombotic phenomena and 1 of 23 will die.\(^ {64}\)

A combination therapy approach may yield the best possible outcomes for patients with cancer cachexia. A randomized phase III trial in 332 patients with cancer-related anorexia/cachexia revealed superior outcomes for patients receiving a combination regimen that included medroxyprogesterone, megestrol acetate, eicosapentaenoic acid and L-carnitine supplementation, and thalidomide, versus therapy with any of the previously discussed single agents.\(^ {65}\) Another phase III trial of 104 patients with advanced gynecologic cancers and cachexia supported the merits of combination therapy; compared with megestrol acetate alone, patients receiving megestrol acetate plus L-carnitine, celecoxib, and antioxidants had improved lean body mass, appetite, and quality of life.\(^ {69}\)

Although cannabinoid-based interventions (eg, dronabinol, cannabis) have some demonstrated efficacy for treating chemotherapy-induced nausea and vomiting and AIDS-related anorexia, the data to support cannabinoid-based interventions for treating anorexia/cachexia in patients with cancer are very limited.\(^ {70}\) A randomized clinical trial of cannabis extract and delta-9-tetrahydrocannabinol in patients with cancer-related anorexia/cachexia syndrome did not demonstrate a benefit of these agents over placebo on appetite and quality of life.\(^ {71}\) Another randomized trial comparing megestrol acetate to dronabinol in treating cancer-associated anorexia revealed megestrol acetate to be superior for promoting weight gain (75% vs 49% of patients) and appetite (11% vs 3%) in patients with advanced cancer.\(^ {72}\) However, to a lesser extent, dronabinol did improve appetite and weight gain in some study patients. Ultimately, for some patients with cancer-related anorexia, cannabinoids could be helpful. However, it is important to note that cannabinoid administration in elderly patients may induce delirium, and providers should be aware of the local state rules and regu-
lations regarding medicinal cannabinoid use.

Nutrition consultation should also be considered, because calorie-dense, high-protein supplementation has demonstrated some efficacy for weight stabilization, although some studies show nutritional interventions to be ineffective. A meta-analysis found that although nutritional intervention does not significantly affect weight gain or energy intake, it can improve some aspects of quality of life, including emotional functioning, dyspnea, and hunger. Nutritional support, including enteral and parenteral feeding as appropriate, should also be considered when the disease or treatment affects the ability to eat and/or absorb nutrients and the patient’s life expectancy is months to years. The goals and intensity of nutritional support change as life expectancy is reduced to weeks to days. Overly aggressive enteral or parenteral nutrition therapies can actually increase the suffering of dying patients.

In addition, a recent randomized controlled trial of patients with cancer enrolled in hospice found that parenteral hydration had no effect on dehydration symptoms such as fatigue and hallucination and had no effect on quality of life or survival. Therefore, instead of artificial hydration and nutrition, palliative care in the final weeks of life focuses on treating dry mouth and thirst, and providing education and support to the patient and family regarding the emotional aspects of withdrawal of nutritional support. Family members should be informed of alternate ways to care for dying patients.

**Nausea and Vomiting:** Chemotherapy-induced nausea and vomiting has a major impact on a patient’s quality of life. Nausea and vomiting induced by chemotherapy or radiation therapy should be managed as outlined in the NCCN Guidelines for Antiemesis. Patients can also experience nausea and vomiting unrelated to chemotherapy and radiation, resulting from gastric outlet obstruction, bowel obstruction, constipation, opioid use, or hypercalcemia. These causes should be identified and treated. Proton pump inhibitors and histamine-2 (H2) receptor antagonists can be used to manage gastritis or gastroesophageal reflux. Gastric outlet obstruction may benefit from treatment with corticosteroids; alternative treatment options include endoscopic stenting or insertion of a decompressing G-tube. Many medications can also cause nausea and vomiting, and blood levels of possible culprits, such as digoxin, phenytoin, car-bamazepine, and tricyclic antidepressants, should be checked.

Nonspecific nausea and vomiting can be managed with dopamine receptor antagonists (eg, prochlorperazine, haloperidol, metoclopramide, olanzapine) or benzodiazepines (anxiety-related nausea). Persistent nausea and vomiting can be treated by titrating dopamine receptor antagonists to maximum benefit and tolerance. For persistent nausea, adding 5-HT3 (5-hydroxytryptamine 3) receptor antagonists and/or anticholinergic agents and/or antihistamines, corticosteroids, continuous or subcutaneous infusion of antiemetics, antipsychotics (eg, olanzapine or haloperidol), and/or cannabinoids can also be considered. Opioid rotation may also help alleviate symptoms. Agents that target the cannabinoid system may offer some efficacy in treating refractory chemotherapy-induced nausea and vomiting. Dronabinol and nabilone are 2 cannabinoid agents approved for treating chemotherapy-induced nausea and vomiting that are refractory to standard antiemetic therapies. Alternative therapies (eg, acupuncture, hypnosis, cognitive behavioral therapy) can also be considered. Palliative sedation (see subsequent section) can be considered as a last resort if intensified efforts by specialized palliative care or hospice services fail.

A systematic review assessed the level of evidence for antiemesis unrelated to chemotherapy. Although the authors concluded that antiemetic recommendations have moderate to weak evidence at best, the strongest evidence supports the use of metoclopramide; studies of multidrug combination therapies do not support their effectiveness.

**Constipation:** Constipation occurs in approximately 50% of patients with advanced cancer and most patients treated with opioids. Although several drugs, including antacids, anticholinergic drugs (antidepressants, antispasmodics, phenothiazines, and haloperidol), and antiemetics are known to cause constipation, opioid analgesics are most commonly associated with constipation. Providers should discontinue any nonessential constipating medications. In addition to physical discomfort, constipation in patients with advanced cancer can cause psychological distress and anxiety regarding continued opioid use. Opioid-induced constipation should be anticipated and treated prophylactically with a stimulating laxative to increase bowel motility with or without

---

© JNCCN—Journal of the National Comprehensive Cancer Network | Volume 14 Number 1 | January 2016
stool softeners. Although little evidence exists on which is the best initial bowel regimen in patients with cancer, one small study compared the use of senna alone versus a senna-docusate combination. The results demonstrated that the addition of the stool softener docusate was not necessary. Increasing intake of fluid and physical activity should also be encouraged, when appropriate. Added dietary fiber may be considered for patients with adequate fluid intake.

If constipation is present, the cause and severity must be assessed. Impaction, obstruction, and other treatable causes, such as hypercalcemia, hypokalemia, hypothyroidism, and diabetes mellitus, should be assessed and treated. Constipation may Also be treated by adding bisacodyl 10 to 15 mg, 2 to 3 times daily with a goal of 1 nonforced bowel movement every 1 to 2 days. If impaction is observed, glycerine suppositories may be administered or manual disimpaction may be performed. If constipation persists, adding other laxatives may be considered, such as rectal bisacodyl once daily or oral polyethylene glycol, lactulose, magnesium hydroxide, or magnesium citrate. If gastroparesis is suspected, the addition of a prokinetic agent, such as metoclopramide, may be considered.

Peripherally acting µ-opioid receptor antagonists may help to relieve opioid-induced constipation (OIC) while maintaining pain management. Recent studies have shown that methylnaltrexone provided effective relief of OIC while preserving opioid-mediated analgesia. Naloxegol, a similar peripherally-acting µ-opioid receptor antagonist, has also been studied for treating OIC in patients receiving chronic opioids for noncancer pain. Gastrointestinal specialists have reported some success using erythromycin for constipation symptoms that do not respond to peripherally acting µ-opioid receptor antagonists such as methylnaltrexone.

Several newer agents have also been examined for treating constipation. Lubiprostone is an orally active prostaglandin analog that activates chloride channels to enhance intestinal fluid secretion. This agent was shown to be effective for treating OIC in patients with chronic noncancer pain. Lubiprostone could be used in combination with a peripherally acting µ-opioid receptor antagonist such as methylnaltrexone. Linaclotide is a selective agonist of guanylate cyclase-C receptors in the intestines to enhance intestinal secretions and has been effective in the treatment of constipation associated with irritable bowel syndrome and chronic idiopathic constipation. The American Gastroenterological Association includes lubiprostone and linaclotide as recommended options for treating constipation associated with irritable bowel disorder.

Based on these results, the NCCN Palliative Care Panel recommends considering 0.15 mg per kilogram of body weight of methylnaltrexone every other day (no more than once/day) for patients experiencing constipation that has not responded to standard laxative therapy. Methylnaltrexone should not be used in patients with a postoperative ileus or mechanical bowel obstruction.

Diarrhea: In patients with cancer, diarrhea can be caused by a number of potential factors, including antitumor treatment-related side effects, infection, antibiotic use, dietary changes, or fecal impaction. Diarrhea is a common side effect of various chemotherapeutics (eg, fluorouracil and irinotecan), as well tyrosine kinase inhibitors and certain biologic agents (eg, ipilimumab, cetuximab, panitumumab). Abdominal and pelvic radiation therapy (alone or as part of chemoradiation regimens) can also induce gastrointestinal toxicity resulting in diarrhea.

The National Cancer Institute Common Toxicity Criteria are typically used for measuring diarrhea in this patient population. The panel recommends that patients be screened to determine the grade of diarrhea. Providers should provide immediate intervention for dehydration based on grade and assess for potential cause(s).

For patients with years, months to months, or months to weeks of estimated life expectancy who have grade 1 or 2 diarrhea, recommendations include hydration and electrolyte replacement (oral or intravenous fluids as appropriate), antidiarrheal medications, and a bland/BRAT (bread, rice, applesauce, toast) diet. For treating grade 2 diarrhea, anticholinergic agents such as hyoscyamine or atropine can be considered. Infection-induced diarrhea should be treated with the appropriate antibiotic. If diarrhea persists, the use of low doses of morphine concentrate can be considered and would be more cost effective than tincture of opium. Patients with persistent grade 2 or grades 3 or 4 diarrhea should receive inpatient treatment. In addition to fluid re-
placement, antidiarrheal therapy, and anticholinergics, octreotide can also be considered.

For patients with weeks to days of estimated life expectancy, the previously discussed interventions can be considered consistent with the goals of care. At-home intravenous hydration may be considered in addition to scopolamine or hyoscymamine. If diar-

rhea persists, consider octreotide or glycopyrrolate. Patients should begin around-the-clock opioids or receive an increased dose of ongoing opioid regi-

ments.

**Malignant Bowel Obstruction:** Malignant bowel obstructions are usually diagnosed clinically and confirmed with radiography. For patients with years to months to live, surgery after CT scan is the main treatment option. Although surgery can lead to improvements in quality of life, surgical risks should be discussed with patients and families. Although surgery is the primary treatment for mali-

gnant obstruction, some patients with advanced dis-

ease or patients in generally poor condition are not fit for surgery and require alternative management to relieve distressing symptoms. Risk factors for poor surgical outcome include ascites, carcinomatosis, palpable intra-abdominal masses, multiple bowel ob-

structions, previous abdominal radiation, advanced disease, and poor overall clinical status. In these patients, medical management can include phar-

cologic measures, parenteral fluids, endoscopic man-

agement, and enteral tube drainage (silicone tubing may offer superior comfort over vinyl).

Pharmacologic management of malignant bowel obstruction can be seen as different for 2 groups of patients: those for whom the goal is to maintain gut function and those for whom gut function is no longer possible. When the goal is maintaining gut func-

tion, patients can be treated with opioids, antiemet-

ics, and corticosteroids, alone or in combination. When gut function is no longer considered possible, pharmacologic options also include somatostatin ana-

glogs (eg, octreotide) and/or anticholinergics. If octreotide is helpful and the patient has a life expect-

cancy of at least 1 month, it may be beneficial to con-

sider a depot form of octreotide once an optimal dose is established. Antiemetics that increase gastrointestinal mobility such as metoclopramide should not be used in patients with complete obstruction, but may be beneficial when obstruction is partial. Use of octreotide is recommended early in the diagnosis be-

cause of its efficacy and tolerability. Despite positive findings from several smaller randomized trials, a recent phase III trial of octreotide in 86 patients with malignant bowel obstruction failed to demonstrate a significant effect of this drug on days free of vomiting, number of vomiting episodes, symptom management, and other secondary endpoints.

A venting gastrostomy tube (inserted by inter-

ventional radiology, endoscopy, or surgery depart-

ments), a percutaneous endoscopic gastrostomy tube, or an endoscopically placed stent can also palliate symptoms of malignant bowel obstruction.

Total parenteral nutrition can be considered to improve quality of life in patients with a life expectancy of years to months. These interventions have been shown to have little positive impact on survival time, but may improve quality of life.

**Fatigue/Weakness/Asthenia:** The data on methylphenidate for treating cancer-related fatigue have been mixed. Although some trials have suggested a dose-dependent benefit of this agent on fatigue symptoms, other studies have failed to produce positive results. Phase III randomized trials of modafinil for treating cancer-related fatigue suggested that modafinil had a modest efficacy and was most effective for those with severe fatigue. For more information, see the NCCN Guidelines for Cancer-

Related Fatigue (available at NCCN.org).

**Sleep/Wake Disturbances:** Patients with cancer often suffer from insomnia or daytime sedation. In a recent study of 442 patients with advanced cancer, 330 (75%) patients were noted to have baseline sleep disturbance as assessed using the Edmonton Symptom Assessment System (ESAS) sleep item.

Patients should first be evaluated for sleep/wake disturbances using, for example, the Epworth Sleepiness Scale. If patients have a history of sleep-disordered breathing (eg, excessive snoring, gasping for air, observed apneas, frequent arousals, sudden involuntary movement of arm or legs during sleep, unexplained daytime drowsiness), polysomnography should be considered. Polysomnography should also be considered for patients with head and neck cancers, because obstructive sleep apnea (OSA) is prevalent in patients with this disease. Primary sleep disorders, such as OSA and periodic limb movement disorder, should be treated with continuous positive airway pressure (CPAP) or BiPAP. Restless leg syndrome, if present, can be treated with ropinirole, pramipex-
ole with pregabalin, or carbidopa-levodopa.\textsuperscript{149–157} Fears and anxiety regarding death and disease should be explored, and other contributing factors to sleep/wake disturbances should be treated, including pain, depression, anxiety, delirium, and nausea. Cognitive behavioral therapy may be effective in treating sleep/wake disturbances in patients with cancer.\textsuperscript{33,158–162}

For refractory insomnia, pharmacologic management includes the short-acting benzodiazepine lorazepam, the nonbenzodiazepine zolpidem, antipsychotic medications such as chlorpromazine, quetiapine, and olanzapine, and sedating antidepressants such as trazodone and mirtazapine.\textsuperscript{163} The panel suggests that mirtazapine may be especially effective in patients with depression and anorexia. Benzodiazepines should be avoided in older patients and in patients with cognitive impairment, because they have been shown to cause decreased cognitive performance.\textsuperscript{164} Caution should be exercised when administering zolpidem due to the known risk of next-morning impairment. In 2013, the US FDA required lower recommended doses of zolpidem (ie, from 10 to 5 mg for immediate-release products and from 12.5 to 6.25 mg for extended-release formulations).\textsuperscript{165}

For refractory daytime sedation, the guidelines suggest several options. The central nervous system stimulants methylphenidate or dextroamphetamine should be given with a starting dose of 2.5 to 5 mg orally with breakfast. If the effect of the drug does not last through lunch, a second dose can be given at lunch, preferably no later than 2:00 PM. Doses can be escalated as needed.\textsuperscript{166} Another option for refractory daytime sedation is the psychostimulant modafinil, which has been approved in adults for excessive daytime sleepiness associated with OSA/hypopnea syndrome (OSAHS), shift work sleep disorder, and narcolepsy.\textsuperscript{167} The panel also recommends caffeine and dextroamphetamine as additional options for refractory daytime sedation. The last dose of caffeine should be given no later than 4:00 PM.

Dying patients should be assessed for their desire to have their insomnia or sedation treated. The doses of their pharmacologic therapies can be adjusted as appropriate. The addition of an antipsychotic drug (chlorpromazine or quetiapine) can be considered in patients whose insomnia is refractory.

Please also see the NCCN Guidelines for Adult Cancer Pain and the NCCN Guidelines for Cancer-Related Fatigue for their discussions on sleep/wake disturbances (available at NCCN.org).

**Delirium:** Delirium should be assessed using the Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition (DSM-IV) criteria.\textsuperscript{168} Reversible causes should be identified and treated appropriately.\textsuperscript{169} Delirium may present as either a hypoactive or a hyperactive subtype.\textsuperscript{170} Recent studies have suggested that hypoactive delirium was the most prevalent subtype in patients under palliative care and that this condition is often underdiagnosed due to its presentation.\textsuperscript{171,172}

Two comprehensive reviews describe the evidence base for recommended pharmacologic and nonpharmacologic treatments for delirium in patients with cancer.\textsuperscript{33,173} Nonpharmacologic interventions (eg, reorientation, cognitive stimulation, sleep hygiene) should be maximized before pharmacologic interventions are used. Delirium-inducing medications (ie, steroids, anticholinergics) should be reduced or eliminated as much as possible.\textsuperscript{174} Benzodiazepines should not be used as initial treatment for delirium in patients not already taking them.

The symptoms of moderate delirium can be managed with oral haloperidol, risperidone, olanzapine, or quetiapine fumarate.\textsuperscript{175–177} The symptoms of severe delirium (ie, agitation) should be managed with antipsychotic, neuroleptic drugs such as haloperidol, olanzapine, or chlorpromazine.\textsuperscript{178} Because of its hypotensive side effect, intravenous chlorpromazine should only be used in bed-bound patients. A benzodiazepine, such as lorazepam, may be added for agitation that is refractory to high doses of neuroleptics.\textsuperscript{179} The presence of therapeutic levels of neuroleptics usually prevents the paradoxical excitation sometimes seen when delirious patients are given lorazepam. The dosages of these symptom-management medications should be titrated to optimal relief. Opioid dose reduction or rotation can also be considered for patients with severe delirium. Caregivers should be supported in caring for their loved one and coping with this distressing condition.

Delirium in patients with advanced cancer and limited life expectancy may shorten prognosis.\textsuperscript{180} In these patients, iatrogenic causes should be eliminated whenever possible. Opioid rotation can be considered (see NCCN Guidelines for Adult Cancer Pain) if the delirium is believed to be caused by neurotoxicity of the current opioid. If delirium is a
result of disease progression, palliative care must be focused on symptom management and family support. Neuroleptic and benzodiazepine medications should have their dose increased and/or their route of administration changed to ensure adequate delirium symptom management. Unnecessary medications and tubes should be removed. For refractory delirium in dying patients, palliative sedation can be considered after consultation with a palliative care specialist and/or psychiatrist. Please also see the NCCN Guidelines for Distress Management (available at NCCN.org) for further discussion of delirium in patients with cancer.

Conclusions

These guidelines are intended to help oncology teams provide the best care possible for patients with incurable cancer. Patients with advanced disease frequently are overly optimistic about their chances of cure, treatment response, symptom relief, and survival. One study found that those who overestimated their survival were more likely to die a bad death. Using a decision aid, Smith et al found that most patients want honest information, even if it is bad news. Although use of the decision aid typically took 20 minutes and was challenging for oncologists, it did not cause patients to give up hope or become distressed. Physician-led discussion of disease progression and death can improve quality of care and quality of life for both patients and families. Providing information in a collaborative manner protects the autonomy of patients to make informed decisions based on potential treatment outcomes. Palliative care can help patients and families set realistic expectations and meet short- and longer-term goals, such as important life-cycle events. Much of the care outlined in these guidelines is geared toward a different hope than that for cure of the disease itself. Even when cure is no longer possible, hope remains: hope for dignity, comfort, and closure and for growth at the end of life. It is our hope that these guidelines will help oncology and palliative care professionals together create a better future for patients, families, and providers.

References


Palliative Care, Version 1.2016


### Individual Disclosures of the NCCN Palliative Care Panel

<table>
<thead>
<tr>
<th>Panel Member</th>
<th>Clinical Research Support/Data Safety Monitoring Board</th>
<th>Scientific Advisory Boards, Consultant, or Expert Witness</th>
<th>Promotional Advisory Boards, Consultant, or Speakers Bureau</th>
<th>Date Completed</th>
</tr>
</thead>
<tbody>
<tr>
<td>Amy Alvarez-Perez, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>6/26/15</td>
</tr>
<tr>
<td>Anthony Back, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>4/14/15</td>
</tr>
<tr>
<td>Justin N. Baker, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>7/26/15</td>
</tr>
<tr>
<td>Anna C. Beck, MD</td>
<td>Pfizer Inc.</td>
<td>None</td>
<td>None</td>
<td>7/16/15</td>
</tr>
<tr>
<td>Susan Block, MD</td>
<td>Branta Foundation</td>
<td>None</td>
<td>None</td>
<td>7/08/15</td>
</tr>
<tr>
<td>Shalini Dalal, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>6/15/15</td>
</tr>
<tr>
<td>Maria Dans, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>6/17/15</td>
</tr>
<tr>
<td>Thomas R. Fitch, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/03/15</td>
</tr>
<tr>
<td>Jennifer Kapo, MD</td>
<td>Smilow Cancer Hospital</td>
<td>None</td>
<td>None</td>
<td>6/15/15</td>
</tr>
<tr>
<td>Jean S. Kutner, MD, MSPH</td>
<td>AHRQ; American Cancer Society; National Heart Lung and Blood Institute; National Institute of Nursing Research; National Institute on Aging; and PCORI</td>
<td>Institute of Medicine</td>
<td>None</td>
<td>6/15/15</td>
</tr>
<tr>
<td>Elizabeth Kvale, MD*</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>8/04/15</td>
</tr>
<tr>
<td>Michael Levy, MD, PhD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>4/14/15</td>
</tr>
<tr>
<td>Sumathi Misra, MD</td>
<td>None</td>
<td>Legal expert for malpractice suits</td>
<td>None</td>
<td>8/04/15</td>
</tr>
<tr>
<td>William Mitchell, MD</td>
<td>Pfizer Inc.</td>
<td>None</td>
<td>None</td>
<td>4/14/15</td>
</tr>
<tr>
<td>Diane G. Portman, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>4/14/15</td>
</tr>
<tr>
<td>Todd M. Sauer, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>11/12/14</td>
</tr>
<tr>
<td>Thomas Smith, MD**</td>
<td>Competitive Technologies, Inc. (makers of Scrambler therapy)</td>
<td>None</td>
<td>None</td>
<td>4/14/15</td>
</tr>
<tr>
<td>David Spiegel, MD</td>
<td>NCI; and National Center for Complementary and Alternative Medicine</td>
<td>Campbell, Erickson, Ference &amp; Hall; County of Santa Clara; Fabian and Clendenin; Law Office of John Halley; and PeerWell</td>
<td>None</td>
<td>6/26/15</td>
</tr>
<tr>
<td>Linda Sutton, MD</td>
<td>GW Pharmaceuticals</td>
<td>None</td>
<td>None</td>
<td>7/15/15</td>
</tr>
<tr>
<td>Eytan Szmuilowicz, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>7/28/15</td>
</tr>
<tr>
<td>Robert M. Taylor</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>7/29/15</td>
</tr>
<tr>
<td>Jennifer Temel, MD</td>
<td>Helsinn Therapeutics, Inc.</td>
<td>None</td>
<td>None</td>
<td>6/04/15</td>
</tr>
<tr>
<td>Roma Tickoo, MD, MPH</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>3/05/15</td>
</tr>
<tr>
<td>Susan G. Urba, MD</td>
<td>Eisai Inc.</td>
<td>None</td>
<td>None</td>
<td>9/04/15</td>
</tr>
<tr>
<td>Elizabeth Weinstein, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>12/07/15</td>
</tr>
<tr>
<td>Finly Zachariah, MD</td>
<td>None</td>
<td>None</td>
<td>None</td>
<td>5/05/15</td>
</tr>
</tbody>
</table>

*The following individuals have disclosed that they have an Employment/Governing Board, Patent, Equity, or Royalty conflict:
Jean Kutner MD, MSPH: American Academy of Hospice and Palliative Medicine
Elizabeth Kvale, MD: Aspire Health Care
Thomas Smith, MD: American Academy of Hospice and Palliative Medicine, and UnitedHealthcare

**The following individuals have disclosed that they have a Spouse/Domestic Partner/Dependent Potential Conflict:
Thomas Smith, MD: UnitedHealthcare
The NCCN Guidelines staff have no conflicts to disclose.